Huawei Chronicles 30 Years of Wireless Innovation in a Documentary for the First Time

Key Message:

• Huawei has officially launched Signals of Change, a four-part documentary series that, for the first time, offers global audiences a comprehensive look at the company's major technological innovations in wireless communications over more than three decades.
• The documentary highlights Huawei's landmark innovations, including Distributed Base Stations, SingleRAN, Massive MIMO, Polar Code, MetaAAU, and "0 Bit 0 Watt".
• Through real-world scenarios such as high-speed rail connectivity, network coverage in extreme environments, and connectivity at major sporting events, the documentary hears from global telecom operators, industry analysts, and other stakeholders to showcase the global impact and value of Huawei's wireless innovations.

SHENZHEN, CHINA – Media OutReach Newswire – 6 November 2026 - Huawei today officially launched Signals of Change, a new documentary series that, for the first time, charts the company's major technological innovations in wireless communications over more than three decades. Produced by Huawei in collaboration with CNN International's brand studio Create, the series will be broadcast worldwide.

Huawei's wireless business began in 1994, but it was in the early 2000s that it began to break into international markets. Huawei developed its distributed base station innovation, marking a historic breakthrough into the European wireless communications market. From its early struggles to gain a foothold to its determined progress in recent years, Huawei has consistently sought to overcome obstacles through innovation and meet challenges with resilience, continuing to advance amid technological transformation and intense market competition.

Through real-world scenarios such as high-speed rail connectivity, network coverage in extreme environments, and connectivity at major sporting events, the documentary hears from representatives of leading global telecom operators, industry analysts, Huawei executives, and R&D experts. It revisits landmark innovations including Distributed Base Stations, SingleRAN, Massive MIMO, and "0 Bit 0 Watt", tracing Huawei's journey from an industry newcomer to a leader in technological innovation and industry development.

Episode 1: Small Station, Giant Leap: How the World Was Connected

From Distributed Base Stations to SingleRAN: Driving Mobile Network Deployment Through Architectural Innovation

On a high-speed train traveling at nearly 350 kilometers per hour, a surgeon can download hundreds of CT scan images over a mobile network to provide timely remote medical consultations. At altitudes exceeding 6,000 meters in the Mount Everest region, scientific researchers can stay connected with colleagues thousands of miles away through real-time video links, enabling remote scientific collaboration. From high-speed railways to the roof of the world, the first two episodes of the documentary explore how mobile communications technology continues to overcome the limitations of speed and geography. To trace the architectural innovations behind these advances, the story takes us back more than two decades to the early days of 3G network deployment in Europe.

In the early 2000s, European telecom operators faced significant challenges in deploying 3G networks, including difficulties in acquiring sites, lengthy deployment cycles, and high costs. In 2004, Huawei engineers visited customer sites to gain firsthand insights into these challenges and pioneered a distributed base station architecture comprising a compact Baseband Unit (BBU) and Remote Radio Units (RRUs). This innovation enabled operators to deploy network equipment more flexibly while significantly reducing network construction costs. Huawei's distributed base stations were first deployed in the Netherlands in 2005, followed by large-scale commercial deployment in Spain in 2006. Over time, the distributed base station became a mainstream architecture for mobile network deployment worldwide.

As the coexistence of 2G, 3G, and other mobile networks created growing challenges of duplicated infrastructure, Huawei made further breakthroughs in key technologies, including GSM multi-carrier digital predistortion (DPD), and introduced its SingleRAN solution. By integrating multiple radio access technologies on a unified hardware platform, SingleRAN enabled operators to deploy different network standards together and smoothly evolve their networks across successive generations of mobile technology. In 2008, a German telecom operator became the first in Germany to deploy Huawei's multi-mode base station solution, marking the beginning of SingleRAN's commercial adoption in Europe. Since then, SingleRAN has been widely deployed around the world, driving the evolution of mobile networks toward multi-band, multi-mode integration while helping operators significantly reduce network deployment and operating costs.

From Massive MIMO to Polar Code Implementation: Turning Cutting-Edge Research into Real-World Applications

At the Nanjing Olympic Sports Center, 62,356 football fans gathered for the Su Super League final. Spectators shared highlights in real time on their smartphones, with photos, videos, and live-streaming data flowing rapidly across mobile networks. This high-density connectivity, featured in Episode 3, reflects the explosive growth in data demand in the mobile internet era. How to accommodate ever-increasing data traffic using limited spectrum resources has long been a major technical challenge for the mobile communications industry.

Huawei has continuously invested in Massive MIMO (Multiple-Input Multiple-Output) research, leveraging innovations such as large-scale antenna arrays to bring this cutting-edge technology from theoretical research to commercial deployment. In 2015, Huawei worked with an operator partner in Shanghai to successfully validate Massive MIMO in a commercial network environment. Today, Massive MIMO has become one of the key technologies underpinning 5G networks, laying a solid technological foundation for the world's transition to the 5G era.

Meanwhile, Huawei has continued to explore innovations in fundamental research. In 2008, Turkish scientist Erdal Arıkan introduced the theory of Polar Codes, opening up a new direction in channel coding technology. Building on this theoretical breakthrough, Huawei invested in Polar Code encoding and decoding algorithms and system-level validation. In 2016, through the efforts of Huawei and global industry partners, Polar Codes were selected by 3GPP as the coding scheme for 5G enhanced Mobile Broadband (eMBB) control channels, becoming an important part of the international 5G standard.

From MetaAAU to "0 Bit 0 Watt": Delivering Superior Network Performance with Ultra-Low Energy Consumption

Episode 4 shifts the focus to the green transformation of wireless networks. As demand for mobile connectivity continues to grow, reducing network energy consumption while meeting rising performance requirements has become a shared challenge for telecom operators worldwide.

In 2021, Huawei launched MetaAAU, its next-generation Massive MIMO product. Through innovations including ultra-large-scale antenna arrays, MetaAAU pushed beyond the performance limitations of conventional antenna architectures. By enhancing network coverage while reducing energy consumption by approximately 30%, MetaAAU has helped operators achieve both higher network performance and greater energy efficiency.

In 2021, Huawei and its European customers jointly introduced the "0 Bit 0 Watt" concept. Through coordinated innovations in hardware, materials, software, and intelligent network management, the solution enables wireless equipment to enter ultra-deep sleep modes during periods of low traffic and wake up on demand, reducing network energy consumption while maintaining user experience. In 2024, the solution received the GSMA GLOMO Award for "Best Mobile Technology Breakthrough", offering a new technological pathway for telecom operators worldwide to advance their green transformation.

A Journey of Relentless Innovation: Driven by Customer Needs and Scientific Advancement

From transforming base station architectures to enabling multi-standard network integration, from breakthroughs in key algorithms to contributing to global standards, and from continuous product evolution to achieving ultra-low energy consumption, Huawei's journey of wireless innovation over more than three decades has been guided by a consistent commitment: addressing customer needs to drive innovation and scientific exploration to push technological boundaries. These efforts have continuously advanced global network capabilities, creating new possibilities for the digital economy and a more connected society.

Looking ahead, Huawei will remain committed to its dual-driver approach to innovation, continue to increase investment in fundamental research and development, respect and protect intellectual property rights, and embrace openness and mutually beneficial collaboration. Working alongside partners worldwide, Huawei aims to advance mobile communications technology and contribute to a thriving global industry ecosystem.

Where to Watch:

Watch the documentary via media's YouTube link, or follow Huawei's official social media channels to discover the full story of the Signals of Change documentary series.

Q1: Why has Huawei chosen to release this documentary series on wireless innovation now?

A: Huawei aims to offer global audiences a comprehensive look at its major technological innovations over more than three decades. Through authentic stories, technological breakthroughs, and industry achievements, the documentary showcases Huawei's capabilities in original innovation and raises awareness of its contributions.

The global mobile communications industry is entering a pivotal stage in the development of next-generation networks. Through this documentary, Huawei hopes to highlight its long-standing commitment to innovation driven by both customer needs and scientific advancement, sustained investment in fundamental research, and collaborative innovation with global partners. Huawei will continue to carry these principles forward as it explores new technologies and contributes to the development of next-generation mobile networks.

Q2: How do the technological innovations featured in the documentary relate to people's everyday lives?

A: The mobile connectivity we take for granted today is built on decades of continuous technological innovation. From distributed base stations that made mobile network deployment more flexible and cost-effective, to SingleRAN, which enabled the integration and smooth evolution of different generations of mobile networks, and Massive MIMO, which dramatically increased network capacity, each breakthrough has expanded the possibilities of mobile communications. More recently, innovations such as MetaAAU and "0 Bit 0 Watt" have helped operators achieve both improved network performance and greater energy efficiency.

Whether staying connected on a high-speed train, sharing memorable moments in a stadium filled with tens of thousands of fans, or accessing reliable mobile services in remote areas, these everyday experiences depend on the combined capabilities of multiple generations of communications technology. The documentary aims to show audiences that the seamless connectivity we expect is the result of generations of technological progress—and that these innovations will continue to shape our digital lives in the years ahead.

Hashtag: #Huawei

The issuer is solely responsible for the content of this announcement.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

Premiums as low as HK$1 per day, simple underwriting and broad cancer drug treatment coverage help customers protect their health and get covered with ease

HONG KONG SAR – Media OutReach Newswire – 9 November 2026 – AIA Hong Kong & Macau announced the launch of FutureShield Cancer Drug Plan ("FutureShield"), a new medical protection insurance plan designed to help customers manage the rising cost of cancer drug treatments and access evolving treatment options with greater confidence. The plan reimburses eligible expenses for covered cancer drugs¹ and supportive medications² prescribed for medically necessary active treatment³ or palliative treatment⁴ of the insured's covered cancer⁵, as long as such medications are prescribed to and received by the insured in a public hospital in Hong Kong or Macau, or in a hospital in the Chinese Mainland.

Cost-Effective, Simplified Underwriting and Broad Cancer Drug Treatment Options

In Hong Kong's public hospitals, certain drugs are self-financed. While assistance programmes are available to eligible patients, they are means-tested and may still involve significant out-of-pocket costs for some families. Statistics show that 50,000 public-hospital patients in Hong Kong required self-financed drugs each year, and amongst them, annual costs can approach HK$1 million.⁶ In some cases, cancer drugs can account for nearly 80% of total cancer treatment costs.⁷

In response to the rising cost of cancer drug treatment, FutureShield offers a cost-effective premium option from as low as HK$1 per day⁸, together with a Covered Cancer Limit of up to HK$5 million⁹, helping customers better manage the financial burden of cancer drug treatment when needed.

To help customers access cancer drug protection more easily, the plan features simplified underwriting based on health-related questions, with no medical examination required. Even individuals with common chronic conditions, such as high blood pressure, high blood sugar or high cholesterol, may still be eligible for coverage. The plan reimburses covered cancer drugs¹ and supportive medications² prescribed to and received by the insured in a public hospital in Hong Kong or Macau, or in a hospital in the Chinese Mainland, including drugs approved in the future¹⁰. This allows customers to stay protected as cancer medicine advances, supporting both current and future treatment needs.

Ms Alice Liang, Chief Proposition & Healthcare Officer of AIA Hong Kong & Macau, said: "Cancer remains one of the most pressing health concerns facing Hong Kong families today. While advances in cancer treatment are creating new possibilities and improving outcomes, the high cost of newer cancer therapies and the longer treatment duration of certain cancers can also create considerable financial pressure for patients and their families.

"FutureShield Cancer Drug Plan reflects AIA's Integrated Healthcare Strategy and our commitment to creating positive social impact. By combining affordable cancer drug protection, simplified underwriting, broad coverage for cancer treatment options and cross-boundary cancer drug support¹¹, we aim to make quality cancer medical treatment more accessible, affordable and effective. Through this customer-centric innovation, we are helping more cancer patients access treatment with greater confidence while supporting our promise to help people live Healthier, Longer, Better Lives."

Supporting Cancer Treatment Across Hong Kong, Macau and the Chinese Mainland

Covered areas of FutureShield include public hospitals in Hong Kong and Macau, as well as hospitals in the Chinese Mainland. In addition, with growing interest in accessing cancer treatment options across Hong Kong and the Mainland Greater Bay Area (GBA)¹², customers may face challenges in identifying suitable medical providers and navigating cross-boundary treatment arrangements. Cross-boundary Cancer Drug Support¹¹, a value-added service, helps customers identify designated medical providers and registered medical practitioners in Hong Kong and the Mainland GBA^12,13 that can provide their prescribed cancer drugs and assists with appointment coordination, providing greater convenience throughout the treatment journey.

Key Features of FutureShield Cancer Drug Plan:

• Cancer Drug Reimbursement Benefit and Supportive Medication Reimbursement Benefit providing reimbursement for eligible expenses of covered cancer drugs¹ and supportive medications² prescribed for medically necessary active treatment³ or palliative treatment⁴ of the insured's covered cancer⁵.
• Future-ready coverage designed to evolve alongside advances in cancer medicine by covering covered cancer drugs¹ and supportive medications² approved by recognised drug regulatory authorities.¹⁰
• Multiple covered areas covering treatment received in public hospitals in Hong Kong and Macau, as well as hospitals in the Chinese Mainland.
• Cross-boundary Cancer Drug Support¹¹ (value-added service) that helps customers navigate treatment pathways and coordinate access to prescribed cancer drugs across Hong Kong and the Mainland GBA¹².
• Resettable Covered Cancer Limits^{5, 14} of up to HK$1 million, replenished every three consecutive years until the total amounts paid under Cancer Drug Reimbursement Benefit and Supportive Medication have reached the Lifetime Cancer Limit¹⁰ of HK$5 million, to support customers throughout longer-term treatment journeys.
• Additional Caring Benefits that provide support beyond cancer drug treatment, including transportation fee subsidy, medical appliances, and wig and voice box expenses.

Frequently Asked Questions

• What is FutureShield Cancer Drug Plan?

FutureShield Cancer Drug Plan is a medical protection insurance plan designed to help customers manage the rising cost of cancer drug treatments and access evolving treatment options with greater confidence. The plan reimburses eligible expenses for covered cancer drugs¹ and supportive medications² prescribed for medically necessary active treatment³ or palliative treatment⁴ of the insured's covered cancer⁵, as long as such medications are prescribed to and received by the insured in a public hospital in Hong Kong or Macau, or in a hospital in the Chinese Mainland, including drugs approved in the future¹⁰. This allows customers to stay protected as cancer medicine advances, supporting both current and future treatment needs.

• How does FutureShield Cancer Drug Plan make cancer drug protection more accessible?

To help customers access cancer drug protection more easily, FutureShield features simplified underwriting based on health-related questions, with no medical examination required. Even individuals with common chronic conditions, such as high blood pressure, high blood sugar or high cholesterol, may still be eligible for coverage. The plan also offers a cost-effective premium option from as low as HK$1 per day⁸, together with a Covered Cancer Limit of up to HK$5 million⁹, helping customers better manage the financial burden of cancer drug treatment when needed.

• How does the Cross-boundary Cancer Drug Support value-added service help customers identify suitable medical providers and navigate cross-boundary treatment arrangements?

FutureShield Cancer Drug Plan includes the Cross-boundary Cancer Drug Support¹¹, a value-added service that helps customers identify designated medical institutions and registered medical practitioners^12,13 in Hong Kong or the Mainland Greater Bay Area that can provide their prescribed cancer drugs and assists with appointment coordination, providing greater convenience throughout the treatment journey.

Remarks:

1	The term "Covered Cancer Drug(s)" means any pharmaceutical or biological medicinal product that is labelled as anti-cancer drug, and which has been approved by a recognised drug regulatory authority of such place where the cancer drug is prescribed to and received by the insured that the cancer drug is for the purposes of Active Treatment or Palliative Treatment and for targeting a Covered Cancer and any related complications (if applicable). Covered Cancer Drug shall specifically exclude any pharmaceutical or biological product used in surgery, radiotherapy, proton therapy or cell therapy. For details of the definition of "Covered Cancer Drug(s)", please refer to the policy contract.
2	The term "Supportive Medication" means any pharmaceutical or biological medicinal product, other than the Covered Cancer Drug, which (a) is prescribed to the insured due to the medically necessary Active Treatment or Palliative Treatment of the insured's Covered Cancer, and (b) has been approved for such use by a recognised drug regulatory authority of such place where the Supportive Medication is prescribed to and received by the insured. Supportive Medication includes anti-nausea drugs, anti-rejection drugs, anti-vertigo drugs, anti-anodyne, and long-term medications which are required by the insured following the Active Treatment or Palliative Treatment of the insured's Covered Cancer such as hormone replacement therapy. For details of the definition of "Supportive Medication", please refer to the policy contract.
3	The term "Active Treatment" means any therapeutic intervention with the aim of prolonging the insured's life, for example, radiotherapy, chemotherapy, targeted therapy, hormonal therapy, immunotherapy, proton therapy and surgery approved for targeting a Covered Cancer and any related complications (if applicable). It does not include any treatment given solely as Palliative Treatment.
4	The term "Palliative Treatment" means treatment intended only to improve the quality of the insured's life in the case of a life threatening covered cancer by relieving pain or alleviating other symptoms of the covered cancer and any related complications (if applicable), or the side effects of its/their treatment, without any attempt at its/their cure.
5	The term "Covered Cancer(s)" refers to "Cancer" which (a) have been occurring for more than 1 year after the issue date or the latest commencement date of the policy, whichever is later, and (b) have been investigated, diagnosed, or treated or when its signs or symptoms have manifested. For details of the definition of "Covered Cancer", please refer to the policy contract. The term "Cancer" means all stages of malignant cancer and carcinoma-in-situ, but will specifically exclude the following: (a) any tumour which is histologically classified as pre-malignant; (b) abnormal lesions of cervix uteri classified as cervical intra-epithelial neoplasia grade I (CIN I) and grade II (CIN II); and (c) any cancer where HIV infection is also present. The cancer must be confirmed by the insured's attending registered medical practitioner in writing and supported by clinical, radiological, histological or laboratory evidence reasonably acceptable to us. Please refer to the policy contract for details and the claim conditions.
6	《公營醫療收費改革 改革公營資助 加強醫療保障》(Unofficial English translation: Public healthcare fees and charges reform, Reforming public healthcare subsidies to enhance medical protection), Hong Kong Health Bureau, 2025
7	《香港癌症治療費用2026丨公私營醫院治癌費用外還有什麼要注意？》(Unofficial English translation: Hong Kong cancer treatment costs 2026: Key considerations beyond public and private hospital expenses), am730, 2026
8	Assuming a 30-year-old non-smoking male, the standard annual premium paid for the first year at the time of application is HK$369 (approximately HK$1 per day). Premium payable is based on the insured's attained age and the applicable annual premium schedule at the time of application or renewal of the cover.
9	The Lifetime Cancer Limit is the maximum aggregate amount paid and/or payable during the lifetime of the insured under the Cancer Drug Reimbursement Benefit and the Supportive Medication Reimbursement Benefit in respect of eligible expenses incurred in public hospitals in Hong Kong and Macau, and in hospitals in Chinese Mainland.
10	FutureShield Cancer Drug Plan only covers Covered Cancer Drugs and Supportive Medications which have been approved for such use by a recognised drug regulatory authority of the place where the medications are prescribed to and received by the insured.
11	The Cross-boundary Cancer Drug Support is a value-added service and does not form part of the contractual terms and benefits of any insurance policy, and is non-guaranteed. The Service is provided by the designated third-party service provider, subject to the terms and conditions applicable to the Service. The Service is provided in Hong Kong and the designated cities within the Mainland GBA and not applicable in Macau. AIA reserves the right to amend, suspend or terminate the Service, any part thereof, service provider(s), or to change any terms and conditions relating thereto at any time without prior notice at its absolute discretion. For details of the Service and applicable limitations, please refer to the service leaflet or contact AIA for enquiry.
12	"Greater Bay Area (GBA)" refers to the Guangdong-Hong Kong-Macau Greater Bay Area. "Mainland GBA" refers to the Guangdong-Hong Kong-Macau Greater Bay Area, excluding Hong Kong and Macau.
13	The designated medical providers and registered medical practitioners referred to above are those within the Service Provider's medical network in Hong Kong and the Mainland GBA that are available under the Cross-boundary Cancer Drug Support. For details, please refer to the service leaflet or contact the Service Provider's customer service hotline at (852) 2607 9655.
14	Covered Cancer Limit and Covered Cancer Sub-limits are applicable to all Covered Cancers suffered by the insured and such limits will be replenished every 3 consecutive years, commencing from the date of first diagnosis of the first Covered Cancer suffered by the insured. Covered Cancer Limit and Covered Cancer Sub-limits shall become zero and the policy will terminate when the total amounts paid under Cancer Drug Reimbursement Benefit and Supportive Medication Reimbursement Benefit during the lifetime of the insured reaches the Lifetime Cancer Limit. Any unused limits of the Covered Cancer Limit and the Covered Cancer Sub-limits cannot be carried forward to the next 3-year period, and the total amount(s) paid out under the Cancer Drug Reimbursement Benefit and the Supportive Medication Reimbursement Benefit within each 3-year period cannot exceed the Lifetime Cancer Limit. The above is subject to policy terms and limits.

Important Information:

• All information above is for reference only and does not constitute any offer and/or insurance product recommendation. The product information in this material does not contain the full terms of the policy. The precise terms and conditions of FutureShield are specified in the policy contract. For the details of the product features, terms and conditions, exclusions, product limitation and key product risks, please refer to the product brochure and policy contract of relevant products or visit the AIA Hong Kong's website. In case you want to read policy contract sample before making an application, you can obtain a copy from AIA. Life insurance policies are long-term contracts of insurance. Should you surrender the policy early, you may receive an amount considerably less than the total amount of premiums paid. You may choose to purchase the above Plan(s) as a standalone plan without purchasing other type(s) of insurance products at the same time. You have the right to purchase FutureShield Cancer Drug Plan as a standalone plan without purchasing other insurance products at the same time.

Hashtag: #AIA #FutureShieldCancerDrugPlan #CancerDrugProtection

The issuer is solely responsible for the content of this announcement.

About AIA Hong Kong & Macau

AIA Group Limited established its operations in Hong Kong in 1931. To date, AIA Hong Kong and AIA Macau have more than 19,000 financial planners^*, as well as an extensive network of independent financial advisors, brokerage and bancassurance partners. We serve over 3.8 million customers^{^}, offering them a wide selection of professional services and products ranging from individual life, group life, accident, medical and health, pension, personal lines insurance to investment-linked assurance schemes with numerous investment options. We are also dedicated to providing superb product solutions to meet the financial needs of high-net-worth customers.

^* As at 30 September 2026
^{^} Including AIA Hong Kong and AIA Macau's individual life, group insurance and pension customers (as at 30 September 2026)

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

AIA Hong Kong & Macau announced the launch of FutureShield Cancer Drug Plan, a new medical protection insurance plan designed to help customers manage the rising cost of cancer drug treatments and access evolving treatment options with greater confidence.